In contrast, both EGFR and HER2 expression has been found in patients with non-small-cell lung cancer with poor prognosis [38], erlotinib was beneficial in those patients in an EGFR-dependent way [39]. Here, ERBB2 is linked to non-small cell lung carcinoma.